title: Choline-PET in prostate cancer management: the point of view of the radiation oncologist.
abstract: Among PET radiotracers, FDG seems to be quite accepted as an accurate oncology diagnostic tool, frequently helpful also in the evaluation of treatment response and in radiation therapy treatment planning for several cancer sites. To the contrary, the reliability of Choline as a tracer for prostate cancer (PC) still remains an object of debate for clinicians, including radiation oncologists. This review focuses on the available data about the potential impact of Choline-PET in the daily clinical practice of radiation oncologists managing PC patients. In summary, routine Choline-PET is not indicated for initial local T staging, but it seems better than conventional imaging for nodal staging and for all patients with suspected metastases. In these settings, Choline-PET showed the potential to change patient management. A critical limit remains spatial resolution, limiting the accuracy and reliability for small lesions. After a PSA rise, the problem of the trigger PSA value remains crucial. Indeed, the overall detection rate of Choline-PET is significantly increased when the trigger PSA, or the doubling time, increases, but higher PSA levels are often a sign of metastatic spread, a contraindication for potentially curable local treatments such as radiation therapy. Even if several published data seem to be promising, the current role of PET in treatment planning in PC patients to be irradiated still remains under investigation. Based on available literature data, all these issues are addressed and discussed in this review.
authors.affiliation: Radiation Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. Electronic address: berardino.de-bari@chuv.ch.
authors.forename: Berardino
authors.initials: B
authors.lastname: De Bari
authors.affiliation: Radiation Oncology Department, Sacro Cuore Hospital, Negrar-Verona, Italy.
authors.forename: Filippo
authors.initials: F
authors.lastname: Alongi
authors.affiliation: Radiation Oncology Department, Hôpitaux Universitaires de Genève (HUG), Geneva, Switzerland.
authors.forename: Laëtitia
authors.initials: L
authors.lastname: Lestrade
authors.affiliation: Médecine Nucléaire, Hospices Civils de Lyon and EA 3738, Université Claude Bernard Lyon 1, Lyon, France.
authors.forename: Francesco
authors.initials: F
authors.lastname: Giammarile
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism*; D001859:Bone Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000556:secondary / Q000628:therapy; D002794:Choline; D005720:Gamma Rays / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D049268:Positron-Emission Tomography / Q000379:methods*; D017430:Prostate-Specific Antigen / Q000378:metabolism*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology / Q000628:therapy
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen; D002794:Choline
keywords: Biochemical relapse; Choline-PET; Prostate cancer; Staging; Treatment planning